Merck   4QRevenue: $11.7 billion (-5%) 4Q Earnings: $1.4 billion (-7%) YTD Revenues: $47.3 billion (-2%) YTD Earnings: $6.7 billion (+6%) Comments: Pharmaceutical sales were down 6% to $10.1 billion, including a 1% percent negative impact due to foreign exchange. Singulair sales were down 67% to $480 million. Cozaar/Hyzaar sales were down 26% to $315 million. Januvia sales were $1.1 billion in the quarter, up 18%. Zetia sales were $676 million, up 6%. Remicade sales were up 8% to $549 millio...